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AP-1 = activator protein-1; ER = estrogen receptor; DCIS = ductal carcinoma in situ; Jab1 = c-jun activation domain binding protein 1; NF =
nuclear factor; RT-PCR = reverse transcriptase-polymerase chain reaction; SAGE = serial analysis of gene expression.
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Introduction
Molecular analysis of breast cancer has revealed that a
large number of genes are differentially expressed at
different stages and in different types of lesions during the
progression of the disease [1–3]. It can be presumed that
among this almost bewildering array is more than one
category of gene. Some genes comprise key and early
saboteurs of the normal cell, whose alteration is a primary
initiating or promoting event. Other genes comprise key
collaborators whose modification confers irresponsible
cellular behaviors in the context of a multicellular
organism, which are nonetheless valuable and bestow
additional advantages to a committed neoplastic cell. But
many other genes can be presumed to represent irrelevant
bystanders and ‘distal chatter’ that results from the
disturbance of the primary or central cell circuitry. In all
cases, these genes have functions in the normal cell, but
these range from the central to the peripheral and from the
crucial to the mundane.
One of the major challenges of the current era of cancer
research, with its explosive growth of profiling data, is to
distinguish between these categories of genes.
Improvements in diagnosis and treatment also depend on
identification of genes that are central to and crucial to the
supremacy of the abnormal cancer cell within tissues.
These are the determinants of independence, enhanced
survival and growth, and the capacity to spread to, squat
within, and thrive in foreign tissues.
The S100 genes were among the ‘first wave’ of genes
detected as differentially expressed between normal
breast and breast cancer cells [4–7], or between different
stages of breast cancer [8–10]. This may reflect their
relatively high levels of expression and a bias of
techniques such as subtraction hybridization that were
employed in the early studies. However, parallel strides in
elucidating their function have taken longer. The small
11 kDa S100 proteins were known to demonstrate
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Abstract
The S100 gene family comprises more than 20 members whose protein sequences encompass at
least one EF-hand Ca2+ binding motif. The expression of individual family members is not ubiquitous
for all tissues and there appears to be an element of tissue-specific expression. Molecular analysis of
breast tumors has revealed that several S100s, including S100A2, S100A4 and S100A7, exhibit
altered expression levels during breast tumorigenesis and/or progression. Subsequent studies have
started to describe a functional role for these S100 proteins as well as their mechanism of action and
the biochemical pathways they modify. The present review outlines what is known about S100A7 in
breast cancer and summarizes the need to better understand the importance of this protein in breast
cancer.
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changes in their expression levels in association with many
facets of normal cell biology, including cell differentiation
and growth [8,11]. But until recently there has been little
compelling evidence for direct involvement with critical
cellular proteins or in defined signaling pathways. It has
therefore been tacitly assumed that they belong to the
bystander group, and represent distal aberrations in
response to nonspecific changes in calcium signaling. The
case for reconsidering their importance is gathering
rapidly, however, with evidence that S100s can interact
with and modulate key molecules and signaling pathways,
and may offer both functional markers and targets for
therapies in the breast cancer cell.
Currently, the most studied S100 genes found to be
highly expressed in breast cancer compared with normal
cells are S100A4 [12] and S100A7 [13]. The S100A2
gene has also been found to have its expression altered,
but in this case is reduced in breast cancer cells [14].
Correlative studies have since shown that S100A4 gene
expression [15,16] and S100A7 gene expression [17] in
breast cancer can relate to the survival of the patient. In
experimental cell models, the expression of S100A4
[6,18] and of S100A7 [19] was also found to confer a
more aggressive behavior in vitro and in vivo. Conversely,
reintroduction of S100A2 expression in already invasive
carcinoma cell lines was found to decrease their
aggressiveness [20].
The regulatory factors controlling transcription of S100A2,
S100A4 and S100A7 remain mostly unknown, but some
clues have started to emerge. Different mechanisms of
action, as indicated by specific interacting protein
partners, have also become apparent. As a result of this
knowledge, it is clear that the alteration of S100 gene
expression can foster specific aspects of the progression
of breast cancer and is associated with a more aggressive
phenotype. This direct connection between S100 gene
expression and breast cancer progression establishes
these genes as potential therapeutic targets in the future,
as well as potential biomarkers to predict the outcome of
the patient.
S100A7 expression in breast cancer and
potential biological importance
In comparison with the other members of the S100 gene
family, S100A7 is less studied but perhaps the most
unique both in terms of structure [21] and in terms of a
prominent association with preinvasive carcinoma. This
gene was originally named psoriasin because it was first
identified as a highly expressed secreted protein in
abnormally differentiated keratinocytes from psoriatic
lesions [22]. It has since been found to be expressed in
association with neoplasia in several tissues including
squamous carcinomas of the head and neck, the cervix
and the lung (Alowami S, Watson PH, unpublished data,
2003), the skin [23], the bladder [24], as well as adeno-
carcinomas of the stomach [25] and the breast [8,9,26,27].
Some of these expression data are consistent with a role
as a chemotactic factor in mediating the inflammatory
response, similar to that initially postulated in psoriasis
[28]. But other data point to an additional intracellular
action within epithelial cells that express the protein.
From the study of S100A7 expression at different stages
of progression in both the skin and the breast, it is clear
that while the protein is not generally expressed in normal
epithelia, an increasing frequency of expression is seen
beginning with early stages of progression [9,23].
S100A7 is expressed in lesions such as hyperplasia and
atypical hyperplasia, but is particularly prominent in
preinvasive carcinoma in situ. In some preinvasive ductal
carcinoma  in situ (DCIS) samples, S100A7 has even
emerged as among the most highly expressed genes
using relatively unbiased serial analysis of gene expression
(SAGE) assays to determine relative global expression
levels [2]. Intriguingly, the expression of S100A7 is then
often downregulated with progression to invasive
carcinoma [9,23,29]. This is a dominant feature of
individual lesions where both preinvasive in situ (DCIS)
components and invasive components can be directly
compared, but is also reflected in a lower frequency of
expression in invasive carcinomas [23,29].
This pattern could indicate a primary role in mediating this
stage of progression or a bystander event associated with
a change in the requirement for this protein. S100A7
expression may contribute to the onset of the invasive
phenotype within the context of the breast duct but
selection pressures might change in the foreign
microenvironment of the stroma, such that S100A7
function may become redundant or less important for
success or survival. S100A7 alterations may be due to
genomic or gene regulation changes within individual cells
or cell selection. Although the 1q21 chromosomal locus
has been fingered by early cytogenetic and loss of
heterozygosity studies as commonly altered in breast
tumor progression [30], S100 genes and S100A7 have
yet to be linked to specific amplification, mutation, or other
genomic events in tumors [27].
Relatively little is known about the regulation of S100A7,
but diverse stress stimuli are implicated in both breast and
skin systems, including UV stimulation, serum depletion,
and loss of substrate attachment [27], that may be
mediated in part through estrogen receptors (ERs) and/or
retinoic acid receptors or activator protein-1 (AP-1)
[8,31,32]. Certainly these are factors that are prominent
within the neoplastic breast duct, where there is
increasing hypoxic stress and disruption of cellular
polarization and basal attachment, but these factors are
less evident in the stroma.155
To resolve the possible role of S100A7 as a primary factor
or as a bystander in early tumor progression, several
additional factors can be considered. These include the
relationship between S100A7 expression and specific
tumor pathologies, parameters and cellular factors, the
relationship with clinical outcome, and the biological
effects of S100A7 when expressed in breast cells in the
laboratory.
Examination of S100A7 and prognostic parameters in
both preinvasive DCIS (n= 136) and four invasive carcinoma
cohorts (n = 57,  n = 79,  n = 122,  n = 246) has high-
lighted consistent associations with ER-negative status in
all series, and with higher nuclear grade, node-positive
status, necrosis and increased inflammation in some
series [17,26,27]. From these studies it is clear that one
of the most intriguing facets of S100A7 expression is its
strong association with the absence of ER expression.
Earlier studies documented a very strong association with
ER-negative carcinomas. Subsequent studies confirmed
this association but also showed expression at lower
frequencies in ER-positive tumors.
We have more recently reassessed this relationship in
larger breast cancer tissue microarray cohorts. S100A7
was expressed in 52% and 53% of ER-negative invasive
tumors in two independent tumor cohorts (n = 122,
n = 246) where the ER status was determined by a ligand-
binding ER assay. Conversely, S100A7 was expressed in
18% and 18% of two other ER-positive invasive tumor
cohorts (n = 129,  n = 151) where the ER status was
determined by a ligand-binding assay and by immuno-
histochemistry, respectively, but often at lower expression
levels. Similar results were also obtained from studies of
smaller cohorts of ER-positive and ER-negative DCIS,
where 65% of ER-negative (n = 52) and 35% of ER-
positive (n = 84) in situ lesions were also S100A7-positive.
In cell lines, S100A7 has been shown to be constitutively
expressed at high levels in some ER-negative breast
carcinoma lines [2] or induced by stress [27], but is
induced by estradiol in ER-positive MCF7 cells [8]. The
ER-positive status is both the hallmark of a distinct
differentiation pathway and phenotypic subgroup, and
also an indicator of a tumor that can respond to estrogen
with the accompanying induction or repression of a
subset of specific estrogen responsive genes. But the
basis for recognition of ER-positive status is in need of
reassessment with the recognition of a second estrogen
receptor, ERβ. Nevertheless, we might therefore
conclude that while estrogen can induce expression of
S100A7 in vitro and in vivo in ER-positive cell lines and
tumors, other differentiation-related factors may dominate
and lead to the highest levels of expression and
functional importance in both preinvasive and invasive
ER-negative tumors.
S100A7 expression in invasive breast tumors was
shown to be associated with poor outcome even within
the already poor prognosis subgroup of ER-negative
tumors [17]. In DCIS, where S100A7 is expressed at
perhaps its highest levels, the association with outcome
is harder to study. Relatively small numbers of DCIS
tumors recur or progress after treatment, and many of
these cases recur as DCIS and are likely to be regrowth
of residual disease. For example, in a small follow-up
study of S100A7 and outcome in 45 DCIS patients
treated by breast-conserving surgery, no relation with
recurrence of DCIS was identified. But since only one
patient experienced recurrence as invasive disease, the
relation with this specific aspect of progression could
not be assessed [29].
Understanding the interactions and function of S100A7
may also help to categorize the gene between primary
factor or bystander. Recent studies employing yeast two-
hybrid approaches have helped to single out several
interacting proteins to implicate different S100 genes in
specific cellular pathways including the receptor of
advanced glycation of end products, which has been
proposed as a possible universal S100 cell surface
receptor [33]. However, in vivo confirmation and
affirmation of functional effects from such interactions is
needed in many cases.
S100A7 has been associated with several proteins
through demonstration of in vitro interaction. These
include homodimerization [34], and interactions with c-
jun activation domain binding protein 1 (Jab1) [19], Ran
binding protein M [35], epidermal fatty acid binding
protein [36], and transglutaminase [37]. In breast cells,
however, only the S100A7–Jab1 interaction has as yet
been shown to illicit a functional effect. S100A7
contains a recently described Jab1-binding domain
[38]. Mutation of key amino acids within this binding site
substantially diminishes the interaction and the
functional effects of the interaction [39]. The interaction
of S100A7 with Jab1 appears to cause a cellular
redistribution of Jab1, resulting in an accumulation in
the nucleus [19]. This observation has been confirmed
in both cell lines and breast tumors expressing S100A7
[29]. The interaction of S100A7 with Jab1 also results
in a stimulation of Jab1 activity, presumed to be due to
its increased nuclear concentration. There is an increase
in the AP-1 activity with induction of AP-1-regulated
genes and downregulation of the negative cell cycle
regulating protein p27Kip1. The latter is probably due to
an elevated rate of degradation; this phenomenon is
observable both in breast cell lines in vitro and in vivo
following overexpression of S100A7 [19], and also in
both  in situ breast tumors and ER-negative invasive
breast tumors in vivo (Emberley E, Watson PH,
unpublished data, 2004).
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In agreement with these molecular alterations, S100A7-
transfected ER-negative breast cells demonstrate
increased growth and invasiveness in in vitro assays.
When injected into the mammary fat pads of mice, these
cells also display increased growth and tumorigenicity.
These properties are all manifested more prominently in
vivo, and may reflect a net consequence of S100A7–Jab1
downstream effects on extracellular parameters [19]; for
example, through the actions of AP-1-dependent genes
such as metalloproteinases and vascular endothelial
growth factor. Effects could impact on survival, such as
through an enhanced HIF-1 [40] and hypoxia response, or
could possibly be mediated through other Jab1 downstream
pathways such as Bcl-3 [41,42] and its effect on NF-κB.
Preliminary analysis of ER-positive MCF-7 cell lines
transfected with S100A7 suggests that some but not all
these Jab1 effects are reproduced in an ER-positive
phenotype (Emberley E, Watson PH, unpublished data,
2003). S100A7 may therefore yet be shown to also
interact with several other proteins in different cellular
locations [43], and some of these interactions may also
have the end result of enhancing invasion [44–46]. But
the current data suggest that the majority of its effects in
the ER-negative phenotype are mediated through the
enhancement of Jab1 activity (Fig. 1). Jab1 itself is
commonly expressed in breast tumors, although the level
of Jab1 was not found to be an independent marker of
outcome in node-negative patients [47]. Further study of
Jab1 activity and specific relationships to interacting
proteins such as S100A7 are needed.
Observations on the context of induction of S100A7
expression, both in vitro in cell lines and in vivo within
breast tumors where S100A7 is related to loss of
substrate adhesion [17], also suggest a possible role in
response to cellular stress leading to anoikis. We
therefore examined S100A7 expression in relation to
anoikis in the MDA-MB-231 breast cell line model. There
was a significant relationship between S100A7 and cell
survival that was paralleled by increased activity both of
the NF-κB pathway, previously shown to lie downstream
of Jab1 [41], and of phospho-Akt. To determine whether
these effects are mediated through the interaction with
Jab1 we generated MDA-MB-231 cells expressing
S100A7 mutated in the region of the putative Jab1
binding domain. The mutated S100A7 protein did not
interact with Jab1 in a yeast two-hybrid assay or exert any
significant Jab1 downstream effects when expressed
within MDA-MB-231 cells. Functional analysis of MDA-
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Figure 1
The influence of S100A7 on the prosurvival and proinvasive pathways is mediated through alterations in gene expression. The interaction of
S100A7 with c-jun activation domain binding protein 1 (Jab1) results in a cellular redistribution of Jab1 to become predominately localized in the
nucleus, where it stimulates gene transcription. Jab1acts as a cofactor to stimulate transcription of genes regulated by the NF-κB, activator protein-
1 and HIF1 transcription factors. Extracellular S100A7 may also interact with the receptor of advanced glycation of end products (RAGE) receptor,
resulting in activation of signal transduction cascades and, ultimately, activation of gene transcription. S100A7 is believed to exert its effects
through Jab1 and other proteins with which it forms an interaction, and one outcome is an alteration in gene transcription.157
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Figure 2
Utilizing serial analysis of gene expression (SAGE) databases that are publicly available from the Cancer Genome Anatomy Project website
(http://cgap.nci.nih.gov), the expression of selected S100 genes were compared between normal and cancer breast libraries. Confirming classical
laboratory methods, SAGE found the expression of S100A2 to be higher in normal tissue than in cancer tissue, as well as S100A4 being found
higher in cancer tissue than in normal breast tissue. S100A7 is one of the highest expressed genes in some ductal carcinoma in situ libraries,
compared with normal breast tissue where expression is almost undetectable. S100A15, which resulted from a gene duplication of S100A7, is not
expressed at the same level as S100A7 in breast cancer. SAGE allows the identification and confirmation of individual gene expression levels
between normal tissues and cancer tissues of the breast.158
MB-231 cells expressing mutated S100A7 confirmed that
the Jab1 binding site is necessary for the effect of
S100A7 on NF-κB, phospho-Akt, and promotion of
tumorigenesis  in vivo [39]. In a cohort of ER-negative
invasive breast tumors, S100A7 expression was found to
be associated with an increase in phospho-Akt (Ser 473)
expression [39]. The mechanism that results in activation
of Akt is unknown but currently under investigation. We
conclude that S100A7 can influence prosurvival cellular
pathways through interaction with Jab1. The
S100A7–Jab1 pathway acts to enhance survival under
conditions of cellular stress that cause anoikis, which may
promote progression of breast cancer.
One issue that arises in interpretation of S100 gene
expression and function in vivo is the close homologies
between different members, and many S100 family
members are clustered relatively near together on chromo-
some 1q21. Until recently it appeared that S100A7 was
relatively distinct, but a recent study has shown that the
S100A7 gene shows evidence of gene duplications that
may also be recent in terms of genome evolution [21]. The
authors identified five S100A7-related sequences in the
S100 cluster, although they reported that only S100A7a
and S100A7c are likely to possess functional promoters.
Further analysis now reveals that S100A7c is the gene
previously known as psoriasin, while S100A7a conforms
to a new S100 gene and has been renamed S100A15
[48]. These two proteins are highly similar. Of their 101
amino acids, only seven are different. One of these amino
acids lies within the conserved Jab1-binding domain, and
we would predict that this difference abolishes any
significant capacity to form an interaction with Jab1 or a
similar mechanism of action. S100A15, like S100A7, has
been found to be expressed in skin, but mRNA expression
was not easily detectable in breast cells or tumors by
sequence-specific RT-PCR analysis (Emberley E, Murphy
LC, Watson PH, unpublished data, 2003).
Furthermore, utilizing the resources within the online SAGE
databases from the National Cancer Institute — Cancer
Genome Anatomy Project website (http://cgap.nci.nih.gov),
the expression of S100A7 and S100A15 can be readily
distinguished from each other based on their individual
SAGE tags (Fig. 2). S100A7 is found to be expressed at a
much higher level than S100A15 (841 tags per 200,000
and nine tags per 200,000, respectively) in the SAGE_
Breast_carcinoma_B_DCIS-4 library. There are additional
SAGE DCIS libraries (SAGE_Breast_carcinoma_B_
BWHT18 and SAGE_Breast_carcinoma_MD_ DCIS)
where S100A15 is not detected but S100A7 is expressed
at much higher levels than in the SAGE_Breast_carcinoma_
B_DCIS-4 library. Thus, although these proteins are highly
similar in amino acid sequence, it appears that their
regulation is nonubiquitous and highly tissue specific, as it is
for all the S100 family members.
Conclusion
Members of the S100 gene family are highly homologous
but, despite this, they appear to have different expression
profiles during breast cancer development. Based on
these expression profiles, S100 proteins are emerging as
potentially useful diagnostic and prognostic tools. For
breast cancer, S100A2, S100A4 and S100A7 appear to
be the important players and, in recent years, a potential
biological mechanism of action for S100A4 and S100A7
has begun to emerge. The interaction of S100A7 with
Jab1 is highlighted by the translocation of Jab1 to the
nucleus, where alterations in gene transcription occur
through Jab1’s activity as a transcriptional cofactor. It is
the increase in production of these gene products that is
presumed responsible for the enhanced growth and
invasive properties that are observed in vitro and in vivo in
the presence of S100A7. Further study of the S100 gene
family in breast cancer will discover new interactions and
modifications of the biochemical pathway that will be a
novel set of targets for therapeutic intervention.
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